Use of genome-wide high-throughput technologies in biomarker development

Biomarkers in Medicine

Volumn 2, Issue 5, 2008, Pages 509-524

  Classen, Sabine ^a   Staratschek Jox, Andrea ^a   Schultze, Joachim L ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Biomaker; Blood; Clinical translation; High throughput technologies; Standardization; Transcriptomics

Indexed keywords

BCR ABL PROTEIN; BIOLOGICAL MARKER; CODEINE; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; HOMOVANILLIC ACID; IMATINIB; IRINOTECAN; METOPROLOL; MICRORNA; PROTEIN MDM2; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; AUTOANALYSIS; BIOINFORMATICS; CLINICAL TRIAL; DISEASE COURSE; DNA MICROARRAY; DRUG METABOLISM; DRUG RESEARCH; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE TECHNOLOGY; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; KIDNEY DISEASE; MALIGNANT NEOPLASTIC DISEASE; METABOLOMICS; NONHUMAN; PROCESS OPTIMIZATION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN SYNTHESIS INHIBITION; PROTEOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TRANSCRIPTOMICS;

EID: 60149111899     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.2.5.509     Document Type: Review

References (127)

1. Phillips C: Online resources for SNP analysis: a review and route map. Mol. Biotechnol. 35, 65-97 (2007).
2. Downes MR, Byrne fC, Pennington SR et al.: Urinary markers for prostate cancer. BJU Int. 99, 263-268 (2007).
3. Mohr S. Liew CC: The peripheral-blood transcriptorne: new insights into disease and risk assessment. Trends Mol. Med. 13, 422-432 (2007).
4. Alizadeh AA, Elsen MB, Davis RE et al.: Distinct types of diffuse large B-cell lymphoma Identified by gene expression profiling. Nature 403, 503-511 (2000).
5. Trusheim MR, Berndt ER, Douglas FL: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug. Discov. 6, 287-293 (2007).
6. Ludwig JA, Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5, 84 5-856 (2005).
7. Kohn EC, Azad N, Annunziata C et al.: Proteomics as a tool for biomarker discovery Dis. Markers 23, 411-417 (2007).
8. Rai AJ, Gelfand CA, Haywood BC et al.: HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5, 3262-3277 (2005).
9. Bailey WJ, Ulrich R: Molecular profiling approaches for identifying novel biomarkers. Expert Opin. Drug. Saf. 3, 137-151 (2004).
10. Woodcock J: The prospects for personalized medicine in drug development and drug therapy. Clin. Pharmacol. Ther. 81, 164-169 (2007).
11. Heijne WH, Kienhuis AS, van Ommen B et al.: Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology. Expert Rev. Proteomics 2, 767-780 (2005).
12. Hood L, Perlmutter RM: The impact of systems approaches on biological problems in drug discovery. Nat. Biotechnol. 22, 1215-1217 (2004).
13. van der Greef J, McBurney RN: Innovation: rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat. Rev. Drug Discov. 4. 961-967 (2005).
14. Eisenhauer EA: Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture. Presented at: The 10th NCI-EORTC Conference on New Druk in Cancer Therapy, Amsterdam. Holland, The Netherlands 16-19 June 1998. Ann. Oncol. 9, 1047-1052 (1998),
15. Adourian A, Jennings E, Balasubramanian R et al.: Correlation network analysis for data integration and biomarker selection. Mol. Biosyst. 4, 249-259 (2008).
16. Liu ET: Expression genomics and drug development: towards predictive pharmacology. Brief Funct. Cenomic. Proteonic. 3, 303-321 (2005).
17. Zhu J, Zhang B, Schadt EE. A systems biology approach to drug discovery. Adv Genet. 60, 603-635 (2008).
18. Woodcock J, Woosley R: The FDA critical path initiative and its influence on new drug development. Annu. Rev. Med. 59, 1-12 (2008).
19. Roach JC, Boysen C, Wang K et al.: Pairwise end sequencing: a unified approach to genomic mapping and sequencing. Genomics 26, 345-353 (1995).
20. Edwards JR, Ruparel H, Ju J: Mass-spectrometry DNA sequencing. Mutat. Res. 573, 3-12 (2005).
21. Mayeux R: Mapping the new frontier: complex genetic disorders. J. Clin. Invest. 115, 1404-1407 (2005).
22. Kingsmore SF. Lindquist IE, Mudge J et al.: Genome-wide association studies: progress and potential for drug discovery and development. Nat. Rev. Drug Discov. 7. 221-230 (2008).
23. Ozaki K, Ohnishi Y. Iida A et al.: Functional SNPs in the lymphotoxin-α gene that are associated with susceptibility to myocardial infarction. Nat Genet. 32, 650 654 (2002).
24. Klein RJ, Zeiss C. Chew EY et al.: Complement factor H polvmorphism in age-related macular degeneration., Science 308, 385-389 (2005).
25. Amos CI, Wu X, Broderick P et al.: Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1, Nat. Genet. 40. 616-622 (2008).
26. Hung RJ. McKay JD. Gaborieau V et al.: A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452, 633-637 (2008).
27. Thorgeirsson TE, Geller F. Sulem P et al.: A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452, 638-642 (2008).
28. Gryshchenko I, Hofbauer S, Stoecher M et al.: MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J. Clin. Oncol. 26, 2252-2257 (2008).
29. Payne S: A genome-wide screen for DNA hypermethylation in prostate cancer identifies novel methylation biomarkers with high specificity for prostate cancer versus benign prostatic hyperplasia. Proceedings of: The 99th Annual Meeting of the Anmerican Association for Cancer Research. San Diego, CA and Philadelphia. PA, USA, 12-16 April 2008 (AACR Abstract-No. 34).
30. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350. 2129-2139 (2004).
31. Capdeville R, Buchdunger E, Zimmermann J et al.: Glivec (ST1571, imatinib), a rationally develope 1, targeted anticancer drug, Nat. Rev. Drug Discov. 1, 493-502 (2002).
32. Paoluzzi L. Singh AS, Price DK et al.: Influence of genetic variants in UGTIAI and UGTIA9 on the in vivo glucuronidation of SN-38. J. Clin. Pharmacol. 44, 854-860 (2004).
33. de Leon J, Susce MT, Murray-Carmichael E: The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol. Diagn. Ther. 10, 135-151 (2006).
34. Petrik J: Diagnostic applications of microarrays. Transfus. Med. 16, 233 247 (2006).
35. Stears RL, Martinsky T. Schena M: Frends in microarray analysis. Nat. Med 9. 140-145 (2003).
36. Weeraratna AT. Nagel JE. de Mello-Coelho V et al.: Gene expression profiling: from microarrays to medicine. J. Clin. Immunol. 24. 213-224 (2004).
37. Abdullah-Sayani A. Bueno-de-Mesquita JM. van de Vijver MJ: Technology insight: tuning into the genetic orchestra using microarrays: limitations of DNA microarrays in clinical practice. Nat. Clin. Pract. 3. 501-516 (2006).
38. Schena M. Shalon D. Davis RW et al.: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467-470 (1995).
39. Gray JW. Collins C: Genome changes and gene expression in human solid tumors. Carcinogenesis 21, 443-452 (2000).
40. Mischel PS. Cloughesy TF, Nelson SF: DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat. Rev. Neurosci. 5, 782-792 (2004).
41. Velculescu VE, Zhang L. Vogelstein B et al.: Serial analysis of gene expression. Science 270, 484-487 (1995).
42. Weigl BH, Bardell RL, Cabrera CR: Lab-on-a-chip for drug development. Adv. Drug Deliv. Rev. 55, 349-377 (2003).
43. Stoughton RB, Friend SH: How molecular profiling could revolutionize drug discovery Nat. Rev. Drug Discov. 4, 345-350 (2005).
44. Lapointe J, Li C, Higgins JP et al.: Gene expression profiling Identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101, 811-816 (2001).
45. Yu YP. Landsittel D. Jing L et al.: Gene expression alterations In prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22. 2790-2799 (2004).
46. Eschrich S, Yang I. Bloom G et al.: Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol. 23, 3526-3535 (2005).
47. Yeoh EJ, Ross ME, Shurtleff SA et al.: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1, 133-143 (2002).
48. Lossos IS, Alizadeh AA, Rajapaksa R et al.: HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood 101, 433-440 (2003).
49. Kohlmann A, Kipps TJ, Rassenti LZ et al.: An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in Leukemia Study prephase. Br. J. Haematol. (2008).
50. Paik S, Shak S, Tang G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351. 2817-2826 (2004).
51. van de Vijver MJ, He YD, van't Veer LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
52. van't Veer LJ, Dai H, van de Vijver MJ et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
53. Dumur CI, Lyons-Weiler M, Sciulli C et al.: Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J. Mol. Diagn. 10, 67-77 (2008).
54. Haab BB, Dunham MJ. Brown PO: Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol. 2(2), RESEARCH0004 (2001).
55. MacBeath G, Schreiber SL: Printing proteins as microarrays for high-throughput function determination. Science 289, 1760-1763 (2000).
56. Borrebaeck CA, Wingren C: High-throughput proteomics using antibody microarrays: an update. Expert Rev. Mol. Diagn. 7, 673-686 (2007).
57. Cho WC: Contribution of oncoproteomics to cancer biomarker discovery. Mol. Cancer 6, 25 (2007).
58. Garcia-Foncillas J, Bandres E, Zarate R et al.: Proteomic analysis in cancer research: potential application in clinical use. Clin. Transl. Oncol. 8, 250-261 (2006).
59. Hanash S: Disease proteomics. Nature 422, 226-232 (2003).
60. Wingren C, Borrebaeck CA: High-throughput proteomics using antibody microarrays. Expert Rev. Proteomics 1, 355-364 (2004).
61. Azad NS, Rasool N, Annunziata CM et al.: Proteomics in clinical trials and practice: present uses and future promise. Mol. Cell. Proteomics 5, 1819-1829 (2006).
62. Paweletz CP, Trock B, Pennanen M et al.: Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers 17, 301-307 (2001).
63. Bentzen SM, Buffa FM, Wilson GD: Multiple biomarker tissue microarrays: bioinformatics and practical approaches. Cancer Metastasis Rev. (2008).
64. Schoenberg Fejzo M. Slamon DJ: Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am. J. Pathol. 159, 1645-1650 (2001).
65. Seligson DB: The tissue micro-array as a translational research tooi for biomarker profiling and validation. Biomarkers 10(Suppl. 1), S77-S82 (2005).
66. Kingsmore SF: Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat. Rev. Drug Discov. 5. 310-320 (2006).
67. Haab BB: Antibody arrays in cancer research. Mol. Cell. Proteomics 4, 377-383 (2005).
68. Huang RP: An array of possibilities in cancer research using cytokine antibody arrays. Expert Rev. Proteomics 4. 299-308 (2007).
69. Stamey TA, Johnstone IM, McNeal JE et al.: Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J. Urol. 167, 103-111 (2002).
70. Gao WM, Kuick R. Orchekowski RP et al.: Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 5. 110 (2005).
71. Miller JC, Zhou H, Kwekel J et al.: Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 3, 56-63 (2003).
72. Mor G, Visintin I, Lai Y et al.: Serum protein markers for early detection of ovarian cancer. Proc. Natl Acad. Sci. USA 102, 7677-7682 (2005).
73. Reynolds MA, Kirchick HJ, Dahlen JR et al.: Early biomarkers of stroke. Clin. Chem. 49, 1733-1739 (2003).
74. Christopherson RI, Stoner K, Barber N et al.: Classification of AML using a monoclonal antibody microarray. Methods. Mol. Med. 125, 241-251 (2006).
75. Zurita AJ, Diestra JE, Condom E et al.: Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours. Br. J. Cancer. 88, 879-886 (2003).
76. Burstein HJ: The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med. 353, 1652-1654 (2005).
77. Lablanca R, La Verde N, Garassino MC: Development and clinical indications of cetuximab. Int. J. Biol. Markers 22, S40-S46 (2007).
78. Buchdunger E. O'Reilly T, Wood J: Pharmacology of Imatinib (ST1571). Eur. J. Cancer 38 (Suppl. 5), S28-S36 (2002).
79. Sorlie T, Perou CM, Tibshirani R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869-10874 (2001).
80. Adamcova M, Simunek T, Kaiserova H et al.: In vitro and In vivo examination of cardiac troponins as biochemical markert of drug-induced cardiotoxicity. Toxicology 237, 218-228 (2007).
81. Kosuge M, Ebina T, Ishikawa T et al.: Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circ. J. 71, 186-190 (2007).
82. Collinson PO, Gaze DC: Biomarkers of cardiovascular damage. Med. Princ. Piact. 16, 247-261 (2007).
83. Fisman EZ, Adler Y, Tenenbaum A: Biomarkers in cardiovascular diabetology: interleukins and matrixins. Adv. Cardiol. 45, 44-64 (2008).
84. Vaidya VS, Ferguson MA, Bonventre JV: Biomarkers of acute kidney injury. Annu. Rev. Pharmacol. Toxicol. 48, 463-493 (2008).
85. Takahashi Y, Ishii Y, Nagata T et al.: Clinical application of oligonucleotlde probe array for full-length gene sequencing of TP53 in colon cancer. Oncology 64, 54-60 (2003).
86. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM: Metabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharmacol. Toxicol. 48, 653-683 (2008).
87. Kell DB: Metabolomics and systems biology: making sense of the soup. Curr. Opin. Microbiol. 7, 296-307 (2004).
88. Lindon JC, Holmes E, Bouard ME et al.: Metabonomics technologies and their applications in physiological monitoring. drug safety assessment and disease diagnosis. Biomarkers 1-31 (2004).
89. Paige LA, Mitchell MW, Krishnan KR et al.: A preliminary metabolomic analysis of older adults with and without depression. Int. J. Geriatr. Psyrhiatry 22, 418-423 (2007).
90. Holmes E, Tsang TM. Huang JT et al.: Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 3, e327 (2006).
91. Kaddurah-Daouk R. McEvoy J, Baillie RA et al.: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiatry 12, 934-945 (2007).
92. Brindle JT, Antti H, Holmes E et al.: Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat. Med. 8, 1439-1444 (2002).
93. Sabatine MS, Liu E. Morrow DA et al.: Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112. 3868-3875 (2005).
94. Yuan K, Kong H, Guan Y et al.: A GC-based metabonomics investigation of type 2 diabetes by organic acids metabolic profile. [ i J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 850, 236-240 (2007).
95. Yang J. Xu G, Zheng Y et al.: Diagnosis of liver cancer using HPLC-based tabono,ics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J. Chromatogr. B. Analyt Technol. Biomed. Life Sci. 813, 59-65 (2004).
96. Fan X, Bai J. Shen P: Diagnosis of breast cancer using HPLC metabonomics fingerprints coupled with computational methods. Conf Prvc. IEEE Eng. Med. Biol. Soc. 6, 6081-6084 (2005).
97. Odunsi K, Wollman RM, Ambrosone CB et al.: Detection of epithelial ovarian cancer using IH-NMR-based metabonomics. Int. J. Cancer 113, 782-788 (2005).
98. Beget RD, Holland RD, Sun J et al.: Metabonomics of acute kidney injury in children after cardiac surgery. Pediatr. Nephrol. (2008) (Epub ahead of print).
99. Clayton TA, Linclon JC, Cloarec O et al.: Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073-1077 (2006).
100. Morvan D, Demidem A: Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethy1nitrosourea reveals drug efficacy and tumor adaptive metabolic pathways. Cancer-Res. 6, 2150-2159 (2007).
101. Hammond ME, Taube SE: Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin. Oncol. 29, 213-221 (2002).
102. Dobbin KK, Zhao Y, Simon RM: How large a training set is needed to develop a classifier for microarray data? Clin. Cancer Res. 14, 108-114 (2008).
103. Wang Y, Miller DJ, Clarke R: Approaches to working in high-dimensional data spaces: gene expression microarrays. Br. J. Cancer 98, 1023-1028 (2008).
104. Ransohoff DF: Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer 4, 309-314 (2004).
105. Combaret V, Bergeron C, Brejon S et al.: Protein chip array profiling analysis of sera from neuroblastoma patients. Cancer Lett. 228, 91-96 (2005).
106. Khan N. Cromer CJ. Campa M et al.: Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonstriall cell lung carcinoma. Cancer 101. 379-384(2004).
107. McShane LM, Altman DG. Sauerbrei W et al.: Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl Cancer Inst. 97, 1180-1184 (2005).
108. Riley RD, Abrams KR, Sutton AJ et al.: Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br. J. Cancer 88, 1191-1198 (2003).
109. Shariat SF, Karam JA, Margulis V et al.: New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int. 101, 675-683 (2008).
110. Carpentier SC, Pants B, Swennen R et al.: Finding the significant markers: statistical analysis of proteornic data. Methods Mol. Biol. 428, 327-347 (2008).
111. Altar CA, Amakye D, Bounos D et al.: A prototypical process for creating evidentiary standards for biomarkers and diagnostics. Clin. Pharmacol. Ther. 83, 368-371 (2008).
112. Tuma RS: Biomarker developers face big hurdles. J. Natl Cancer Inst. 100, 456-457, 461 (2008).
113. Cobb JP, Mindrinos MN, Miller-Graziano C et al.: Application of genome-wide expression analysis to human health and disease. Proc. Natl Acad. Sci. USA 102, 4801-4806 (2005).
114. Debey S. Schoenbeck U, Hellmitch M et al.: Comparison of different Isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell types. Pharmacogenomics J. 4, 193-207 (2004).
115. Debey S, Zander T. Brors B et al.: A highly standardized, robust, and cost-effective, method for genome-wide transcriptome analysis of peripheral blood applicable to large-scale clinical trials. Genomics 87, 653-664 (2006).
116. Brazma A, Hingamp, P, Quackenbush J et al.: Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 29, 365-371 (2001).
117. Mitchell SA. Brown KM. Henry MM et al.: Inter-platform comparability of microarrays in acute lymphoblastic leukemia. BMC Genomics 5, 71 (2004).
118. Irizarry RA. Warren D, Spencer F et al.: Multiple-laboratory comparison of microarray platforms. Nat. Methods 2, 345-350 (2005).
119. Patterson TA, Lobenhofer EK. Fulmer-Smentek SB et al.: Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat. Biatechnol. 24, 1140-1150 (2006).
120. Shi L. Reid LH, Jones WD et al.: The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24, 1151-1161 (2006).
121. Shippy R, Fulmer-Smentek S, Jensen RV et al.: Using RNA sample titrations to assess microarray platform performance and normalization techniques. Nat. Biotechnol. 24, 1123-1131 (2006).
122. Walker BA, Leone PE, Jenner MW et al.: Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 108 1733-1743 (2006).
123. Garraway LA, Sellers WR: From integrated genomics to tumor lineage dependency. Cancer Res. 66, 2506-2508 (2006).
124. Garraway LA, Widlund HR. Rubin MA et al.: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122 (2005).
125. Lastowska M, Viprey V. Santibanez-Koref M et al.: Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 26, 7432-7444 (2007).
126. Mao X, James SY, Yanez-Munoz RJ et al.: Rapid high-resolution karyotyping with precise identification of chromosome breakpoints. Genes Chromosoines Cancer 46, 675-683 (2007),
127. Yamamoto G, Nannya Y, Kato M et al.: Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am. J. Hum. Genet. 81, 114-126 (2007).